Following this activity, participants should be able to: [1] Discuss the updated NCCN Guidelines and application of immune checkpoint inhibitors (ICIs) for clinical management of locally advanced/metastatic esophagogastric/esophagogastric junction (EGJ) cancer. [2] Evaluate available clinical evidence for biomarker-directed treatment with ICIs for frontline treatment of locally advanced/metastatic esophagogastric/EGJ cancer, especially in patients with microsatellite instability high (MSI-H)/mismatch repair deficient (dMMR) tumors. [3] Integrate nutritional support for patients with locally advanced/ metastatic esophagogastric/EGJ cancer.
- Provider:National Comprehensive Cancer Network
- Activity Link: https://education.nccn.org/node/96037
- Start Date: 2024-10-28 05:00:00
- End Date: 2024-10-28 05:00:00
- Credit Details: AAPA Category 1 Credit™️: 1.0 hours
AMA PRA Category 1 Credit™️: 1.0 hours
Nursing: 0.75 hours
Pharmacy: 1.0 hours - Commercial Support: Source: AbbVie (Any division) - Amount: 0.0 - Is Kind Support: False Source: AstraZeneca (Any division) - Amount: 0.0 - Is Kind Support: False Source: Coherus BioSciences - Amount: 0.0 - Is Kind Support: False Source: Daiichi Sankyo, Inc. - Amount: 0.0 - Is Kind Support: False Source: Eisai, Inc. - Amount: 0.0 - Is Kind Support: False Source: Genentech (Any division) - Amount: 0.0 - Is Kind Support: False Source: GlaxoSmithKline - Amount: 0.0 - Is Kind Support: False Source: Janssen (Any division) - Amount: 0.0 - Is Kind Support: False Source: Merck (Any division) - Amount: 0.0 - Is Kind Support: False Source: Novartis Corporation Pharmaceuticals - Amount: 0.0 - Is Kind Support: False Source: Sanofi S.A. - Amount: 0.0 - Is Kind Support: False
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: No, it's free
- Measured Outcome: Learner Knowledge, Learner/Team Competence, Learner/Team Performance
- Provider Ship: Directly Provided
- Registration: Open to all
Subscribe
Login
0 Comments
Oldest